Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) fell 6.6% on Friday . The stock traded as low as $0.56 and last traded at $0.57. 601,900 shares were traded during mid-day trading, an increase of 16% from the average session volume of 518,888 shares. The stock had previously closed at $0.61.

Several research firms have weighed in on NVCN. ValuEngine downgraded shares of Neovasc Inc (US) from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Zacks Investment Research cut shares of Neovasc Inc (US) from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $5.19.

The stock has a market cap of $44.99, a price-to-earnings ratio of 2.11 and a beta of -0.07.

A hedge fund recently bought a new stake in Neovasc Inc (US) stock. Virtu KCG Holdings LLC purchased a new position in shares of Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 108,132 shares of the medical equipment provider’s stock, valued at approximately $149,000. Virtu KCG Holdings LLC owned about 0.14% of Neovasc Inc (US) as of its most recent filing with the Securities and Exchange Commission (SEC). 19.22% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Neovasc Inc (US) (NVCN) Trading Down 6.6%” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at

About Neovasc Inc (US)

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with's FREE daily email newsletter.